20,041 Shares in Cencora, Inc. $COR Acquired by Private Management Group Inc.

Private Management Group Inc. bought a new stake in Cencora, Inc. (NYSE:COR) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 20,041 shares of the company’s stock, valued at approximately $6,009,000.

A number of other institutional investors also recently added to or reduced their stakes in COR. Atlantic Edge Private Wealth Management LLC grew its stake in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares in the last quarter. Costello Asset Management INC acquired a new stake in Cencora in the first quarter worth about $28,000. University of Texas Texas AM Investment Management Co. bought a new position in Cencora in the 1st quarter valued at about $39,000. Caitong International Asset Management Co. Ltd acquired a new position in Cencora during the 2nd quarter valued at about $61,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in shares of Cencora during the 2nd quarter worth about $61,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insiders Place Their Bets

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the sale, the chief executive officer directly owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. The trade was a 7.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 46,640 shares of company stock valued at $14,099,338 in the last 90 days. Corporate insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on COR shares. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. TD Cowen upped their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Wells Fargo & Company lifted their price target on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Robert W. Baird boosted their price objective on Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, UBS Group raised their target price on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $371.09.

Cencora Stock Up 1.0%

Shares of Cencora stock opened at $365.56 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 12-month low of $223.92 and a 12-month high of $369.38. The firm has a market capitalization of $70.87 billion, a PE ratio of 37.61, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. The stock’s fifty day moving average is $327.70 and its 200-day moving average is $304.66.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same quarter last year, the business posted $3.34 EPS. Cencora’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is presently 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.